{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:53:27Z","timestamp":1794092007477,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Microbiome"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is a severe public health problem associated with a disordered gut microbiome. However, the functional alterations of microbiota and their cross talk with metabolism pathways based on disease severity remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We performed metagenomics and untargeted metabolomics in a cohort of 68 patients with CKD of differing severities and 20 healthy controls to characterize the complex interplay between the gut microbiome and fecal and serum metabolites during CKD progression. We identified 26 microbial species that significantly changed in patients with CKD; 18 species changed as the disease progressed, and eight species changed only in a specific CKD group. These distinct changes in gut microbiota were accompanied by functional alterations in arginine and proline, arachidonic acid, and glutathione metabolism and ubiquinone and other terpenoid-quinone biosynthesis pathways during CKD progression. Further metabolomic analyses revealed that the distributions of toxic and pro-oxidant metabolites from these four essential metabolic pathways varied in the feces and serum as CKD progressed. Furthermore, we observed a complex co-occurrence between CKD severity-related bacteria and the characterized metabolites from the four essential metabolic pathways. Notably,\n                      <jats:italic>Ruminococcus bromii<\/jats:italic>\n                      , fecal hydroquinone, and serum creatinine were identified as the main contributors to the integrated network, indicating their key roles in CKD progression. Moreover, a noninvasive model including\n                      <jats:italic>R. bromii<\/jats:italic>\n                      and fecal hydroquinone, L-cystine, and 12-keto-tetrahydro-LTB4 levels classified the CKD severity (area under the curve [AUC]:\u2009&gt;\u20090.9) and had better performance than the serum creatinine level for mild CKD (\n                      <jats:italic>AUC<\/jats:italic>\n                      : 0.972 vs. 0.896).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Perturbed CKD severity-related gut microbiota may contribute to unbalanced toxic and pro-oxidant metabolism in the gut and host, accelerating CKD progression, which may be an early diagnostic and therapeutic target for CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40168-022-01443-4","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T04:03:49Z","timestamp":1673237029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["Perturbed gut microbiome and fecal and serum metabolomes are associated with chronic kidney disease severity"],"prefix":"10.1186","volume":"11","author":[{"given":"Haichao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisima","family":"Ainiwaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanlong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"Collaboration, GBDCKD","year":"2020","unstructured":"Collaboration, GBDCKD. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709\u201333.","journal-title":"Lancet"},{"key":"1443_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, et al. Chronic kidney disease. Lancet. 2021;398:786\u2013802.","journal-title":"Lancet"},{"key":"1443_CR3","doi-asserted-by":"publisher","first-page":"e007525","DOI":"10.1136\/bmjgh-2021-007525","volume":"7","author":"T Liyanage","year":"2022","unstructured":"Liyanage T, et al. Prevalence of chronic kidney disease in Asia: a systematic review and analysis. BMJ Glob Health. 2022;7:e007525.","journal-title":"BMJ Glob Health"},{"key":"1443_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12967-018-1756-4","volume":"17","author":"YY Chen","year":"2019","unstructured":"Chen YY, et al. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med. 2019;17:5.","journal-title":"J Transl Med"},{"key":"1443_CR5","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1136\/gutjnl-2019-319766","volume":"69","author":"X Wang","year":"2020","unstructured":"Wang X, et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut. 2020;69:2131\u201342.","journal-title":"Gut"},{"key":"1443_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/00325481.2020.1744335","volume":"132","author":"X Hu","year":"2020","unstructured":"Hu X, et al. Characterizing the gut microbiota in patients with chronic kidney disease. Postgrad Med. 2020;132:495\u2013505.","journal-title":"Postgrad Med"},{"key":"1443_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00424-020-02352-x","volume":"472","author":"NL Rukavina Mikusic","year":"2020","unstructured":"Rukavina Mikusic NL, Kouyoumdzian NM, Choi MR. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch. 2020;472:303\u201320.","journal-title":"Pflugers Arch"},{"key":"1443_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.7150\/ijbs.37421","volume":"16","author":"IW Wu","year":"2020","unstructured":"Wu IW, et al. Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels in chronic kidney disease: discovery and validation study. Int J Biol Sci. 2020;16:420\u201334.","journal-title":"Int J Biol Sci"},{"key":"1443_CR9","doi-asserted-by":"crossref","unstructured":"Kidney disease: improving global outcomes blood pressure work, G., KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99:S1-S87","DOI":"10.1016\/j.kint.2020.11.003"},{"key":"1443_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1186\/s13063-022-06562-9","volume":"23","author":"EA Vermeulen","year":"2022","unstructured":"Vermeulen EA, et al. Reversal of arterial disease by modulating magnesium and phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease. Trials. 2022;23:769.","journal-title":"Trials"},{"key":"1443_CR11","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.7150\/thno.41725","volume":"10","author":"IW Wu","year":"2020","unstructured":"Wu IW, et al. Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease. Theranostics. 2020;10:5398\u2013411.","journal-title":"Theranostics"},{"key":"1443_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-019-0458-7","volume":"25","author":"S Yachida","year":"2019","unstructured":"Yachida S, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 2019;25:968\u201376.","journal-title":"Nat Med"},{"key":"1443_CR13","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/bioinformatics\/bty528","volume":"34","author":"J Chong","year":"2018","unstructured":"Chong J, Xia J. MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data. Bioinformatics. 2018;34:4313\u20134.","journal-title":"Bioinformatics"},{"key":"1443_CR14","doi-asserted-by":"publisher","first-page":"W572","DOI":"10.1093\/nar\/gkaa254","volume":"48","author":"S Nagpal","year":"2020","unstructured":"Nagpal S, et al. MetagenoNets: comprehensive inference and meta-insights for microbial correlation networks. Nucleic Acids Res. 2020;48:W572\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"681\u2013701","key":"1443_CR15","first-page":"e10","volume":"34","author":"J Mayneris-Perxachs","year":"2022","unstructured":"Mayneris-Perxachs J, et al. Microbiota alterations in proline metabolism impact depression. Cell Metab. 2022;34(681\u2013701):e10.","journal-title":"Cell Metab"},{"key":"1443_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jmii.2016.08.016","volume":"51","author":"LH Liu","year":"2018","unstructured":"Liu LH, et al. Citrobacter freundii bacteremia: risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018;51:565\u201372.","journal-title":"J Microbiol Immunol Infect"},{"key":"1443_CR17","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1093\/infdis\/jiaa692","volume":"223","author":"L Liu","year":"2021","unstructured":"Liu L, et al. Citrobacter freundii activation of NLRP3 inflammasome via the type VI secretion system. J Infect Dis. 2021;223:2174\u201385.","journal-title":"J Infect Dis"},{"key":"1443_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000342627","volume":"34","author":"SD Rodrigues","year":"2012","unstructured":"Rodrigues SD, et al. Plasma cysteine\/cystine reduction potential correlates with plasma creatinine levels in chronic kidney disease. Blood Purif. 2012;34:231\u20137.","journal-title":"Blood Purif"},{"key":"1443_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/bs.aambs.2016.06.002","volume":"96","author":"B Sampaio-Maia","year":"2016","unstructured":"Sampaio-Maia B, et al. The role of the gut microbiome on chronic kidney disease. Adv Appl Microbiol. 2016;96:65\u201394.","journal-title":"Adv Appl Microbiol"},{"key":"1443_CR20","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1038\/s41598-017-02989-2","volume":"7","author":"S Jiang","year":"2017","unstructured":"Jiang S, et al. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Sci Rep. 2017;7:2870.","journal-title":"Sci Rep"},{"key":"1443_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2021.110300","volume":"110","author":"K Coello","year":"2021","unstructured":"Coello K, et al. Affective disorders impact prevalence of Flavonifractor and abundance of Christensenellaceae in gut microbiota. Prog Neuropsychopharmacol Biol Psychiatry. 2021;110: 110300.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1443_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.886196","volume":"12","author":"RP Hong","year":"2022","unstructured":"Hong RP, et al. The difference of gut microbiota and their correlations with urinary organic acids between autistic children with and without atopic dermatitis. Front Cell Infect Microbiol. 2022;12: 886196.","journal-title":"Front Cell Infect Microbiol"},{"issue":"15","key":"1443_CR23","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.3390\/ijms20153683","volume":"20","author":"T Wang","year":"2019","unstructured":"Wang T, et al. Arachidonic acid metabolism and kidney inflammation. Int J Mol Sci. 2019;20(15):3683.","journal-title":"Int J Mol Sci"},{"key":"1443_CR24","doi-asserted-by":"publisher","first-page":"116306","DOI":"10.1016\/j.bone.2021.116306","volume":"156","author":"X Li","year":"2022","unstructured":"Li X, et al. Metabolomics-driven of relationships among kidney, bone marrow and bone of rats with postmenopausal osteoporosis. Bone. 2022;156:116306.","journal-title":"Bone"},{"key":"1443_CR25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.taap.2004.11.016","volume":"204","author":"TY Aw","year":"2005","unstructured":"Aw TY. Intestinal glutathione: determinant of mucosal peroxide transport, metabolism, and oxidative susceptibility. Toxicol Appl Pharmacol. 2005;204:320\u20138.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1443_CR26","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1083\/jcb.201804161","volume":"217","author":"A Bansal","year":"2018","unstructured":"Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018;217:2291\u20138.","journal-title":"J Cell Biol"},{"key":"1443_CR27","first-page":"1097","volume":"29","author":"L Pache de Faria Guimaraes","year":"2014","unstructured":"Pache de Faria Guimaraes L, et al. N-acetyl-cysteine is associated to renal function improvement in patients with nephropathic cystinosis. Pediatr Nephrol. 2014;29:1097\u2013102.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1443_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/antiox11050989","volume":"11","author":"F Galli","year":"2022","unstructured":"Galli F, et al. Vitamin E (alpha-tocopherol) metabolism and nutrition in chronic kidney disease. Antioxidants (Basel). 2022;11(5):989.","journal-title":"Antioxidants (Basel)"},{"key":"1443_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11306-019-1625-z","volume":"16","author":"D Blackmore","year":"2020","unstructured":"Blackmore D, et al. Metabolomic profile overlap in prototypical autoimmune humoral disease: a comparison of myasthenia gravis and rheumatoid arthritis. Metabolomics. 2020;16:10.","journal-title":"Metabolomics"},{"key":"1443_CR30","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","volume":"11","author":"G Lee","year":"2020","unstructured":"Lee G, et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun. 2020;11:4982.","journal-title":"Nat Commun"},{"key":"1443_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/CIRCRESAHA.119.316394","volume":"126","author":"X Yan","year":"2020","unstructured":"Yan X, et al. Intestinal flora modulates blood pressure by regulating the synthesis of intestinal-derived corticosterone in high salt-induced hypertension. Circ Res. 2020;126:839\u201353.","journal-title":"Circ Res"},{"key":"1443_CR32","doi-asserted-by":"publisher","first-page":"101484","DOI":"10.1016\/j.beem.2021.101484","volume":"35","author":"CM Mosterd","year":"2021","unstructured":"Mosterd CM, et al. Intestinal microbiota and diabetic kidney diseases: the role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression. Best Pract Res Clin Endocrinol Metab. 2021;35:101484.","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Microbiome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-022-01443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40168-022-01443-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-022-01443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T19:00:24Z","timestamp":1692298824000},"score":1,"resource":{"primary":{"URL":"https:\/\/microbiomejournal.biomedcentral.com\/articles\/10.1186\/s40168-022-01443-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1186\/s40168-022-01443-4","relation":{},"ISSN":["2049-2618"],"issn-type":[{"value":"2049-2618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"14 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Shanghai Tenth People\u2019s Hospital\u2019s Institutional Ethics Committee approved all protocols (SHYS\u2013IEC\u20135.0\/22K162\/P01). Furthermore, we informed all patients of the study\u2019s purpose, and they provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}